CA2630037C — Methods for isolating propargylated aminoindans
Assigned to Teva Pharmaceutical Industries Ltd · Expires 2015-03-31 · 11y expired
What this patent protects
Disclosed is a process for isolating from a reaction mixture a salt of a mono-propargylated aminoindan having the structure (I) wherein R1 is H, hydroxyl, alkoxy or (II) wherein Y is 0 or S; R2 and R3 is each independently, C1-8 alkyl, C6-12 aryl, C6-12 aralkyl, each optionally h…
USPTO Abstract
Disclosed is a process for isolating from a reaction mixture a salt of a mono-propargylated aminoindan having the structure (I) wherein R1 is H, hydroxyl, alkoxy or (II) wherein Y is 0 or S; R2 and R3 is each independently, C1-8 alkyl, C6-12 aryl, C6-12 aralkyl, each optionally halo substituted, or hydrogen ; where the reaction mixture further comprises a solven, a primary aminoindan having the structure (III) wherein R1 is defined as above, and a tertiary aminoindan having the structure (IV) the process comprising d) adding an acid to the reaction mixture; e) crystallizing the mono-propargylated aminoindan under conditions suitable for the formation of a crystalline salt of the mono-propargylated aminoindan ; and f) recovering the crystalline salt of the mono- propargylated aminoindan, wherein the process is performed without addition of an organic solvent. Also disclosed are the crystalline diastereomeric salts produced by the process and pharmaceutical compositions containing the salts.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.